In wake of a CAR-T re­struc­tur­ing, No­var­tis says it’s ready to hunt a pi­o­neer­ing OK for lead pro­gram

No­var­tis is still in the race to win the world’s first ap­proval for a pi­o­neer­ing CAR-T treat­ment.

The phar­ma gi­ant $NVS pulled back the veil from their Phase II study of their CAR-T CTL019, reg­is­ter­ing an im­pres­sive 82% com­plete re­mis­sion rate among the 50 chil­dren and young adults with B-cell acute lym­phoblas­tic leukemia. And with no deaths, though sig­nif­i­cant ev­i­dence of tox­i­c­i­ty, No­var­tis says it will be ready to file for an ap­proval ear­ly on in a loom­ing 2017.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters